Geurts, Maarten H.
Gandhi, Shashank
Boretto, Matteo G.
Akkerman, Ninouk http://orcid.org/0000-0003-0547-3993
Derks, Lucca L. M. http://orcid.org/0000-0001-9836-5558
van Son, Gijs http://orcid.org/0000-0003-0572-3243
Celotti, Martina
Harshuk-Shabso, Sarina
Peci, Flavia
Begthel, Harry
Hendriks, Delilah http://orcid.org/0000-0003-1159-5946
Schürmann, Paul
Andersson-Rolf, Amanda
Chuva de Sousa Lopes, Susana M.
van Es, Johan H.
van Boxtel, Ruben http://orcid.org/0000-0003-1285-2836
Clevers, Hans http://orcid.org/0000-0002-3077-5582
Funding for this research was provided by:
Cancer Research UK (C6307/A29058, C6307/A29058)
Article History
Received: 17 May 2022
Accepted: 7 August 2023
First Online: 17 August 2023
Competing interests
: H.C. is an inventor on several patents related to organoid technology; his full disclosure is given at ExternalRef removed. H.C. is currently head of pharma Research Early Development (pRED) at Roche. H.C. holds several patents on organoid technology. Their application numbers, followed by their publication numbers (if applicable), are as follows: PCT/NL2008/050543, WO2009/022907; PCT/NL2010/000017, WO2010/090513; PCT/IB2011/002167, WO2012/014076; PCT/IB2012/052950, WO2012/168930; PCT/EP2015/060815, WO2015/173425; PCT/EP2015/077990, WO2016/083613; PCT/EP2015/077988, WO2016/083612; PCT/EP2017/054797, WO2017/149025; PCT/EP2017/065101, WO2017/220586; PCT/EP2018/086716, n/a; and GB1819224.5, n/a. The remaining authors declare no competing interests.